Incanthera delighted with skin cancer asset Sol, with clinical results ‘beyond expectations’

Join in on the conversation here




In an interview with London South East, the Incanthera Chairman Tim McCarthy and CEO Dr Simon Ward put the Aquis-listed cancer drug company in context and explain about the successful clinical trials of their skin cancer cream Sol.

Incanthera are a cancer drug development specialist which was spun out of the Institute of Cancer Therapeutics on the Bradford University campus 10 years ago.

Tim McCarthy, Chairman said: “We look at targeted medicines in the onclogy field. We want to target those medicines so that we get the results we are looking for in the most efficient and safe way. The aim of the company is to deliver medicines which are more effective than we currently have. The market for these drugs is clearly enormous, so if we get it right we will have it right for both patients and investors as well.

“We have a very special arrangement with the Institute of Cancer. They hold a share stake in Incanthera and have developed a pipeline agreement whereby they get first rights to anything in our area. This has recently been renewed for another 10 years, and out of that we have built our portfolio as well as from products from outside.

Dr Simon Ward CEO added: “Sol is designed to try and address the skin cancer challenge. In the last 10 years we have seen a 45% increase in melanoma, which is one of the skin cancers which is particularly dangerous, and it is now affecting younger people.

“Over the past six months Sol has done extremely well in clinical trials and we have been delighted with progress. We put it through an efficacy test and a safety test, does it work, is it safe, and it come out covered in glory. It has exceeded our expectations to a considerable degree.”


You might like

© 2022 The Latest StockMarket News and Interviews